GW Pharma Bets On Europe For Epidiolex Growth
Sales Of Cannabinoid Steadily Rise In US
Executive Summary
The company expects the first ever plant-derived cannabinoid to be authorized in Europe to benefit from having already been used by over 1,100 patients with hard-to-treat forms of epilepsy in early access programs.
You may also be interested in...
UK’s NICE Not Convinced By Cannabis-Based Medicines
New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.